Epigenomics Appoints Thomas Taapken as New CFO

13-Jan-2011 - Germany

Epigenomics AG  announced Dr. Thomas Taapken as new Chief Financial Officer (CFO) succeeding the company’s current CFO Oliver Schacht, PhD, effective April 1st, 2011. As previously announced in December 2010, Oliver Schacht will leave effective March 31st, 2011. Oliver Schacht and Thomas Taapken will work closely together to ensure an ordered and structured transition during Q1 2011.

Taapken will join Epigenomics from Biotie Therapies Corp. (Finland), where he currently holds the position of CFO and is a member of the Executive Management Team. He was appointed to this position in 2008, following a business combination between Biotie Therapies and elbion NV, where Taapken had been CFO since 2005. His extensive international experience in the life sciences industry includes further positions as Investment Partner at DVC Deutsche Venture Capital from 2003 to 2005 and San Francisco-based US venture capital firm Burrill & Company from 1998-2002. He also worked several years at Sanofi-Aventis in the United States and Germany, managing corporate venture capital activities, as well as in the areas of corporate & business development and research. Throughout his career, he has been involved in numerous transactions spanning acquisitions, mergers, divestitures and as well as private and public offerings.

Other news from the department people

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance